Results 111 to 120 of about 1,652 (181)

A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma

, 2018
Purpose: The WEE1 tyrosine kinase regulates G2–M transition and maintains genomic stability, particularly in p53-deficient tumors which require DNA repair after genotoxic therapy.
Ahmed Diab, Neal D. Futran, Laura Q.M. Chow, Cristina P. Rodriguez, Eduardo Méndez, Rafael Santana-Davila, Michael C. Kao, Eric Q. Konnick, Sharat Raju, R. Alex Harbison, Ganesh M. Mugundu, Renato Martins   +11 more
core   +1 more source

ACTR-10. PHASE 0 TRIAL OF AZD1775 IN FIRST-RECURRENCE GLIOBLASTOMA PATIENTS [PDF]

Neuro-Oncology, 2016
Nader Sanai, Jing Li, Julie Boerner, Harshil Dhruv, Michael Berens, Patricia LoRusso   +5 more
openaire   +1 more source

Additional file 2: of Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint

, 2018
Figure S2. Effects of AZD1775 plus olaparib on SSB accumulations, PARP trapping and prolonged mitosis in GC cells. (a-c) after drug treatment as indicated, proteins extracted from whole cell lysates or chromatin were probed with indicated antibodies ...
Cheng Zhang (70708), Xiaotian Zhang (529088), Lin Shen (507259), Xiaoting Lin (2608585), Dongshao Chen (4684342), Bin Dong (147019), Zhongwu Li (413576), Jing Gao (69330)   +7 more
core   +1 more source

WEE1 inhibitors trigger GCN2-mediated activation of the integrated stress response. [PDF]

Nat Commun
Tjeerdsma RB, Ng TF, Roorda M, Bianchi D, Yang S, Bonnet C, VanInsberghe M, Everts M, Bakker FJ, de Boer HR, Moatti N, Hustedt N, Yin JZ, Hoeg L, Leibovitch M, Sicheri F, van Oudenaarden A, de Jong S, van den Berg J, Tanenbaum ME, Brummelkamp TR, Durocher D, van Vugt MATM.   +22 more
europepmc   +2 more sources

A Phase I Study of Nab-Paclitaxel, Gemcitabine and AZD1775 for Treatment of Metastatic Adenocarcinoma of the Pancreas: ECOG-ACRIN EA2131. [PDF]

Clin Colorectal Cancer
Eads JR, Lee JW, Chee CE, Meropol NJ, Benson AB, Catalano P, Dotan E, Cardin DB, O'Dwyer PJ.   +8 more
europepmc   +1 more source

WEE1 kinase in cancer: Molecular mechanisms and inhibitor insights. [PDF]

EXCLI J
Kumar A, Paudel KR, Kaur R, Bhatia R.
europepmc   +1 more source

Momentum contrast-enhanced multimodal representation learning for drug synergy prediction. [PDF]

Bioinformatics
Gu Y, Huang X, Shi L, Chen L, Duan G, Yan C.   +5 more
europepmc   +1 more source

Selective Macrocyclic WEE1 Kinase Inhibitors with Strong Efficacy against Patient-Derived Colorectal Cancer Organoids. [PDF]

J Med Chem
Syphers JL, Wright JA, Kumar A, To N, Elson L, Krämer A, Müller S, Morasch V, Chang A, Young S, Sloan EK, de Nys R, Silva TN, Vrbanac L, Barratt KR, Leeflang J, Hasan ST, Gable RW, Knapp S, Worthley DL, Mukherjee S, Stockton K, Woods SL, Priebbenow DL, Baell JB.   +24 more
europepmc   +1 more source

WEE1 Inhibitor AZD1775 as a Promising Therapeutic Approach for Ovarian Cancer

International Journal of Cell Science & Molecular Biology, 2017
openaire   +1 more source

Correction: Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia. [PDF]

Cancer Cell Int
Bell HL, Blair HJ, Singh M, Moorman AV, Heidenreich O, van Delft FW, Lunec J, Irving JAE.   +7 more
europepmc   +1 more source